WO2005030235A1 - Methode de traitement du ginseng pour un usage medicinal, et composition - Google Patents

Methode de traitement du ginseng pour un usage medicinal, et composition Download PDF

Info

Publication number
WO2005030235A1
WO2005030235A1 PCT/JP2004/014265 JP2004014265W WO2005030235A1 WO 2005030235 A1 WO2005030235 A1 WO 2005030235A1 JP 2004014265 W JP2004014265 W JP 2004014265W WO 2005030235 A1 WO2005030235 A1 WO 2005030235A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
composition
acid
effect
processing
Prior art date
Application number
PCT/JP2004/014265
Other languages
English (en)
Japanese (ja)
Inventor
Yuusuke Mori
Naoaki Morihara
Takahiro Yamakawa
Toshinobu Morita
Kazuhiko Imamura
Original Assignee
Wakunaga Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakunaga Pharmaceutical Co., Ltd. filed Critical Wakunaga Pharmaceutical Co., Ltd.
Priority to JP2005514260A priority Critical patent/JP4767686B2/ja
Publication of WO2005030235A1 publication Critical patent/WO2005030235A1/fr
Priority to HK07103793.6A priority patent/HK1096042A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms

Definitions

  • the present invention relates to a method for processing ginseng and a composition obtained by the processing.
  • Priority is claimed on Japanese Patent Application No. 2003-339752, filed on September 30, 2003, the content of which is incorporated herein by reference.
  • Ginseng has been used in China since ancient times and is widely used as a Chinese medicine. Ginseng is known to have a medicinal and preventive effect on arteriosclerosis, hyperlipidemia, thrombosis, hypertension, decreased immune function, decreased liver function, tumor, hyperglycemia, stress, and the like. However, their effects were not fully satisfactory.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 3-277246
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2002-348245
  • An object of the present invention is to provide a processing method for improving the efficacy of ginseng and a composition obtained by the processing.
  • the inventors of the present invention have conducted intensive studies based on the above-described problems, and as a result, have been found to include a step (a) of bringing ginseng into contact with a microorganism or an enzyme and a step (b) of reacting the same with an acid or an alkali.
  • the present inventors have found that the effect of ginseng is significantly improved by performing ginseng, and completed the present invention.
  • the present invention includes a step (a) of bringing ginseng into contact with a microorganism or an enzyme, and a step (b) of reacting ginseng with an acid or an alkali.
  • the present invention relates to a method for processing ginseng, wherein the processed ginseng is further processed in the remaining steps after the processing.
  • a step (a) of bringing ginseng into contact with a microorganism or an enzyme and a step (b) of reacting ginseng with an acid or an alkali are carried out in this order for processing. It relates to a method of processing ginseng.
  • the present invention also relates to a method for processing ginseng, wherein the step (a) may be a step of contacting with an enzyme, and the step (b) may be a step of reacting with an acid.
  • the present invention also relates to a composition obtained by a method for processing ginseng, comprising a step (a) of contacting with a microorganism or an enzyme and a step (b) of reacting with an acid or an alkali. .
  • the present invention provides a food containing the above composition.
  • the ginseng processing method of the present invention does not require special operations and facilities. Also, for processing The resulting composition exhibits an extremely high hepatoprotective effect (improving hepatic function), anti-atherosclerosis, anti-aging effects, etc., and thus can be widely used as foods, pharmaceuticals and cosmetics. Monkey
  • An object of the present invention is to provide a processing method for improving the efficacy of ginseng and a composition obtained by the processing.
  • the ginseng used in the present invention includes seven ginseng (Panax notoginseng (Burk.) FH and hen), t3 ⁇ 4reijin (Panax ginseng and A.
  • the whole plant can be used.
  • roots, rhizomes, stems, branch roots, whiskers, tuberous roots, leaves, flowers, fruits, seeds, buds, baskets, etc. can be used alone or in combination, and preferably roots or rhizomes can be used.
  • the plant can be used after crushing, crushing, repairing, cutting, roasting, and processing such as Z or drying.
  • the ginseng used in the present invention or the ginseng processed in the step (a) and step Z or step (b) according to the present invention is obtained by extracting a plant with a polar solvent or edible oil.
  • the obtained extract, its diluted solution, concentrated solution, extract, and dried product obtained by drying it may be used.
  • polar solvents used for extraction include water; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, and 1-butanol; ethers such as 1,4-dioxane; ketones such as acetone; Tolyls; mixtures of these and the like.
  • Preferred are water, methanol, ethanol and mixtures thereof, particularly preferably water, ethanol and mixtures thereof.
  • Ginseng extract can be produced by a method generally known in the art, for example, by adding the above-mentioned polar solvent to a plant or its dried product obtained by pulverizing, crushing or cutting the plant. At 100 ° C, preferably 20-70 ° C for 10 minutes to 24 hours, preferably 30 minutes to 10 hours.If necessary, remove insolubles by filtration, centrifugation, etc., and concentrate. Can be performed. Further, if necessary, it can be purified by washing with a non-polar solvent such as ethyl acetate, getyl ether and hexane, and extracting with water.
  • a non-polar solvent such as ethyl acetate, getyl ether and hexane
  • the reaction with a microorganism in the processing method of the present invention can be performed by a generally known method.
  • a microorganism or a microorganism previously cultured in an appropriate medium, a ginseng plant, an extract thereof, or a product obtained by processing the same in step (b), or a product obtained by dissolving or suspending the extract in water , Etc. can be mixed and reacted.
  • carbohydrates glucose, sucrose, etc.
  • proteins rice bran, bran, etc.
  • the temperature during the reaction is not particularly limited as long as it is within the activity temperature range of the microorganism. 10-50 ° C is preferred 20-40 ° C is more preferred.
  • the target substance can be obtained by removing the insolubles by heat treatment and operations such as Z or filtration or centrifugation and concentrating or drying.
  • microorganism used for the reaction with the microorganism in the processing method of the present invention include, for example, Ashergillus genus (eg, Aspergillus japonicus, Aspergillus flavus, Aspergillus wentu, Aspergillus niger, Aspergillus niger awamori, Aspergillus oryzae, Aspergillus pulverlentus and the like) ), Notochinoles (f column, Bacillus acidopullalyticus, Bacillus
  • Ashergillus genus eg, Aspergillus japonicus, Aspergillus flavus, Aspergillus wentu, Aspergillus niger, Aspergillus niger awamori, Aspergillus oryzae, Aspergillus pulverlentus and the like
  • Notochinoles f column, Bacillus acidopullalyticus, Bacillus
  • amyloliquefaciens Bacillus subtilis, Bacillus licheniformis, Bacillus cereus, Bacillus circulans, Bacillus licheniformis, Bacillus polymyxa, etc.), Fukutonoku Shinoresu genus ([Retsue is, Lactobacillus brevis, Lactobacillus pentoaceticus, Lactobacillus pastorianus, Lactobacillus Lactobacillus casei, Lactobacillus cucumeris, Lactobacillus bulgaricus , Lactobacillus delbruecku, Lactobacillus jugurti ⁇ Lactobacillus helveticus,
  • Lactobacillus plantrum Lactobacillus acidophilus and the like
  • microorganisms such as lactic acid bacteria, yeast, and filamentous fungi belonging to the genus Rhizopus (eg, Rhizopus delemar, Rhizopus oryzae) and the like.
  • Aspergillus, Bacillus and Lactobacillus are preferred. Is particularly preferred.
  • Aspergillus niger, Aspergillus niger awamon, and Aspergillus oryzae 3 are preferred, and Aspergillus oryzae is particularly preferred.
  • These microorganisms may be used alone or in combination.
  • the enzyme reaction in the processing method of the present invention can be performed by a generally known method.
  • ginseng plants, their extracts, or those obtained by processing the same in step (b), or those obtained by dissolving or suspending the extracts in water require the required amount of enzymes, such as ginseng. 0.001 to 1% by weight, preferably 0.05 to 0.3% by weight, and with appropriate stirring 0 to 90 ° C, preferably 20 to 70 ° C, more preferably 30 to 50 ° C Leave for 1 hour and 1 week, preferably 5 hours and 5 days. Thereafter, the enzyme is inactivated by a heat treatment, and if necessary, for example, filtration, Z or centrifugation is performed to remove insolubles, followed by concentration or drying to obtain the desired product.
  • enzymes such as ginseng. 0.001 to 1% by weight, preferably 0.05 to 0.3% by weight, and with appropriate stirring 0 to 90 ° C, preferably 20 to 70 ° C, more preferably 30 to 50 ° C Leave for 1 hour and 1 week, preferably 5 hours and 5 days. Thereafter, the enzyme is inactivated by a heat
  • Examples of the enzymes used in the enzymatic reaction in the processing method of the present invention include, for example, senorylase, hemicenorelase, xylanase, lactase, pectinase, protease, ⁇ -galactosidase, j8-galactosidase, ⁇ -amylase, ⁇ -amylase.
  • Examples include amylase, hesperidinase and naringinase.
  • ratatase Preferred are ratatase, xylanase, cellulase, hemicellulase, j8-galactosidase and pectinase, and particularly preferred is
  • These enzymes can be used in combination of two or more depending on the reaction temperature.
  • the reaction with an acid or alkali in the processing method of the present invention can be performed by a generally known method.
  • a ginseng plant, an extract thereof, or a product obtained by processing the same or an extract thereof in step (a) may be used at a concentration of 0.001 to 50%, preferably 0.5 to 10%.
  • Dissolve or suspend in acid or alkali Thereafter, heat treatment is performed at 80 to 150 ° C, preferably 100 to 130 ° C, for 5 minutes to 14 hours, preferably for 30 minutes to 12 hours.
  • the desired product can be obtained by removing insolubles by removing the solvent by operations such as neutralization, filtration and Z or centrifugation, removing the solvent, and concentrating or drying.
  • the acid or alkali used for the acid or alkali reaction in the processing method of the present invention is not particularly limited.
  • the acid include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and nitric acid, acetic acid, citric acid, phosphoric acid, malic acid, succinic acid, fumaric acid, tartaric acid, lactic acid, and vinegar (for example, Vinegar and synthetic vinegar such as grain vinegar and fruit vinegar).
  • these acids may be used alone or in combination of two or more.
  • the alkali include alkalis such as sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, and sodium dihydrogen phosphate.
  • the pH of the acid is preferably 1.0 to pH ⁇ 4.5 in the reaction with an acid, and more preferably 2.0 ⁇ pH ⁇ 4. 0, and more preferably 2.0 ⁇ pH 3.8.
  • the pH of anorecali is preferably 7.5 to pH 11.0, more preferably 8.0 ⁇ pH ⁇ 10.0, and further preferably 8.5 ⁇ pH ⁇ 10.0.
  • the method for processing ginseng of the present invention includes a step (a) of bringing ginseng into contact with a microorganism or an enzyme, and a step (b) of reacting ginseng with an acid or an alkali.
  • the order can be arbitrarily selected, but it is preferred that the step (a) of bringing ginseng into contact with a microorganism or an enzyme and the step (b) of reacting with an acid or an alkali are sequentially reacted in this order.
  • the reaction with an enzyme is preferred in step (a)
  • the reaction with an acid is preferred in step (b) from the viewpoint of improving the medicinal effect of ginseng.
  • the reaction is more preferably performed sequentially in the order of the step of contacting with the enzyme and the step of reacting with the acid.
  • the composition obtained by the processing method of the present invention can be used after further extraction and purification with Z or a column.
  • the extraction can be performed by the above method.
  • column purification for example, after dissolving or suspending the composition of the present invention in purified water, it is added to a column of a giant reticulated resin, and unnecessary substances are washed with purified water, followed by 70-90%
  • the desired product can be obtained by eluting with ethanol and concentrating the eluate. If necessary (for example, for decolorization), the ethanol eluate may be passed through an ion exchange resin column, and then eluted with 70-90% ethanol.
  • the composition of the present invention can be obtained by concentrating the eluate.
  • the giant reticulated resin used in the present invention is, for example, a porous polymer polymerized with styrene, diphenylstyrene or a_methylacrylic ester, and has a large surface area. It is the one in which fine continuous pores called pores develop into the inside of polymer particles. It is known from this structural feature that it efficiently adsorbs organic substances, and is used for concentration and purification of natural products and fermentation products. As the giant reticulated resin, a generally known resin is used.
  • Amberlite XAD-1 and Amberlite XAD-2 (all manufactured by OM & Haas Co., Ltd.), DIAION HP20, DIAION HP21, Sepabeads SP 825, Seno ⁇ Beads SP850, Seno ⁇ Beads SP207, DIAION HP2MG (Above, manufactured by Mitsubishi Chemical Corporation) and the like.
  • the ion exchange resin used in the present invention does not require a special one, and a generally known ion exchange resin can be used.
  • the ion exchange resin include a strongly acidic cation exchange resin, a weakly acidic cation exchange resin, a strongly basic anion exchange resin, a weakly basic anion exchange resin, and a mixed resin. Fats, weakly acidic cation exchange resins and mixed resins.
  • composition obtained by the processing method of the present invention, an extract thereof, or a purified product of a column has various medicinal effects (preventive and therapeutic effects)!
  • hepatoprotective effect effect of improving liver function
  • anti-atherosclerosis anti-aging, anti-tumor effect, anti-hyperlipidemia, anti-thrombosis, blood pressure lowering effect, immune function improvement, blood sugar lowering effect, analgesic effect, inotropic effect
  • It has an anti-inflammatory effect, a peripheral blood flow improving effect, a hemostatic effect, an antioxidant effect, an anti-stress effect and the like. Therefore, it may be used for their treatment.
  • the composition of the present invention, the extract thereof, and the purified product of the column can be used in combination with each other. Also, a plurality of compositions obtained by the method of the present invention may be used in combination!
  • composition obtained by the processing method of the present invention, an extract thereof, or a purified product of a column can be used as a food, drug, cosmetic or oral composition (dentifrice) according to the intended use.
  • composition of the present invention When used as food, other food materials can be blended with the composition of the present invention.
  • pulp polishes konkon, mariazami, nutmeg, lycopodium, isoflavone, royal jelly, lactoferrin and its extract, liver extract, etc.
  • it is intended to provide an antioxidant effect use astaxanthin, grape seeds (proantasia ), Vitamin E, polyphenol, power techin and the like.
  • licorice, peony, oak, ginseng, grape seeds (proanthocyanin), linseed seeds, and the like and extracts thereof can be blended.
  • nutrient kinase, linseed seeds and the like and extracts thereof can be combined.
  • vanapa, salsia blolonga, salsia reticularata, white sweet potato, yacon, tonpuri, reishi and its extract, procya-gin and the like can be added.
  • ⁇ -aminobutyric acid for the purpose of imparting blood pressure lowering effect, use ⁇ -aminobutyric acid, sardine peptide, casopeptide, tuna peptide, propolis, kale, reishi, nose, grape seed (proanthocyanin), etc. and extracts thereof Can be blended. These compounds may be used alone or in combination of two or more.
  • the food materials that can be blended in the composition of the present invention are not limited to the above-mentioned materials, and can be appropriately blended according to the use and purpose thereof.
  • Excipients can be added as needed.For example, cellulose, crystalline cellulose, lactose, sucrose fatty acid ester, lactose, reduced maltose, pregelatinized starch, pine fiber, dextrin, no index, etc. can be appropriately added. Can be.
  • the form of the food can be, for example, a solid food, a creamy or jam-like semi-liquid food, a gel-like food, a tablet, a powder, a caplet, and a soft capsule or a hard capsule.
  • the capsule film is gelatin, for example, in order to prevent insolubilization of the film, phosphatidylethanolamine and soybean lecithin and egg yolk lecithin containing the phosphatidylethanolamine are added to the total content of the capsule.
  • an amino sugar a saccharide having an amino group such as darcosamine, ⁇ -acetyl darcosamine, galactosamine, ⁇ -acetylgalactosamine, ⁇ -acetylneuraminic acid, etc.
  • chitosan which is a polymer of dalcosamine
  • inositol phosphate derivatives such as phytic acid, and Kuen acid
  • organic acid 0.5 05 20 wt%
  • Soft capsules containing the composition obtained by the processing method of the present invention, an extract thereof, or a purified product of a column as a filling content can be produced by a generally known method.
  • gelatin may be dissolved in water (at this time, heat may be added. Preservatives, amino acids and the like can be added. ), The resulting solution is dried to a moisture content of 5-20%, more preferably 7-15% to obtain a capsule shell.
  • the filled contents obtained by adding the composition of the present invention, soybean lecithin, phytic acid and, if necessary, an excipient to the capsule film are added in the form of liquid, suspension, paste, powder or granules. It can be manufactured by filling or encapsulating the filling content with the above capsule film.
  • composition of the composition obtained by the processing method of the present invention, the extract thereof, or the purified product of the column can be arbitrarily selected in the amount contained in food.
  • the cosmetic is used in accordance with the intended use within a range that does not impair the effects of the present invention. And 0.00000 to 10.0% by weight, preferably 0.00001 to 5.0% by weight, based on the total weight of the cosmetic. Further, if necessary, vitamin C, vitamin E, astaxanthin, grape seed (proanthocyanin), collagen, chondroitin, dalcosamine and the like can be appropriately selected and used. These may be used alone or in combination of two or more.
  • composition obtained by the processing method of the present invention, an extract thereof or a purified product of a column is used as a shampoo component
  • the ion content may be adjusted within the range not impairing the effects of the present invention in accordance with the intended use.
  • Ingredients commonly used in cosmetics, such as anti-dandruff agents, chelating agents, pH adjusters, electrolytes, coloring agents, fragrances, cosmetic ingredients for scalp or hair care, etc. can be blended. These components may be used alone or in combination of two or more.
  • the amount of the composition obtained by the processing method of the present invention, the extract thereof, or the purified product of the column contained in the shampoo can be arbitrarily selected.
  • composition obtained by the processing method of the present invention its extract or purified column is used as a component of an oral composition (such as a dentifrice), an abrasive, a wetting agent, a binder, Blowing agents and other components generally used in oral compositions (dentifrices) can be blended. These components may be used alone or in combination of two or more.
  • an extract thereof, or a purified column is used as an oral composition, the amount of the composition contained therein can be arbitrarily selected.
  • composition obtained by the processing method of the present invention its extract or purified column is used as a medicament, injection, parenteral administration such as rectum, oral administration in solid or liquid form, etc.
  • the amount of the composition, extract or column purified product obtained by the processing method of the present invention contained in the drug can be arbitrarily selected.
  • compositions according to the present invention for injection may include pharmaceutically acceptable sterile water, non-aqueous solution, suspension or emulsion.
  • suitable non-aqueous carriers, diluents, solvents or vehicles that can be used above include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl ethyl oleate.
  • Compositions for such injections may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • compositions are mixed with a sterilizing agent, for example by filtration through a bacteria-retaining filter, or just prior to use, in the form of a sterile solid composition that can be dissolved in sterile water or some other sterile injectable medium. By doing so, it can be sterilized.
  • a sterilizing agent for example by filtration through a bacteria-retaining filter, or just prior to use, in the form of a sterile solid composition that can be dissolved in sterile water or some other sterile injectable medium. By doing so, it can be sterilized.
  • Examples of solid preparations for oral administration include capsules, tablets, pills, powders, and granules.
  • the compound of the present invention is generally mixed with at least one inert diluent, for example, sucrose, lactose, starch and the like.
  • the formulation may further comprise additional substances other than inert diluents, such as lubricants (eg, magnesium stearate, etc.) in the usual formulation.
  • lubricants eg, magnesium stearate, etc.
  • Tablets and pills are further provided with an enteric coating.
  • Liquid preparations for oral administration include inert diluents commonly used by those skilled in the art, such as pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing water. Is mentioned.
  • the compositions can also include adjuvants such as wetting agents, emulsifying, suspending, sweetening, flavoring, and flavoring agents.
  • adjuvants such as wetting agents, emulsifying, suspending, sweetening, flavoring, and flavoring agents.
  • excipients such as cocoa butter and suppository wax in addition to the compound of the present invention.
  • the dose of the composition obtained by the processing method of the present invention, its extract or purified product of the column depends on the composition to be administered, the properties of the extract or purified product of the column, the administration route, and the desired treatment period. And other factors. Generally, about 0.1-100 mg / kg per day, especially about 0.5-50 mg / kg, is preferred. If desired, the daily dose can be divided and administered in 2 to 4 times.
  • Example 1 the present invention will be described by way of examples, but these do not limit the present invention.
  • Example 1 the present invention will be described by way of examples, but these do not limit the present invention.
  • Example 5 Og of the powder obtained in Example 1 is dissolved in 100 mL of purified water. This solution is added to a column of Diaion HP20 (manufactured by Mitsubishi Iridaku Co., Ltd.) 200CC, and unnecessary substances are washed away with 10 times the column volume of purified water. Then elute with 5 times the column volume of 70% ethanol. The eluate is collected and passed through ion-exchange resin “Diaion SK104” (manufactured by Mitsubishi Iridaku Co., Ltd.), and then eluted with 70% of the same column volume of ethanol. The eluate was concentrated and dried under reduced pressure to obtain 400 mg of a solid powder.
  • Diaion HP20 manufactured by Mitsubishi Iridaku Co., Ltd.
  • Wistar male rats (6 weeks old) were used for the experiment after pre-breeding for 1 week.
  • the experimental groups consisted of four groups: a normal group, a control group, and seven ginseng fields. 3.OgZkg-administered group and a group treated with seven ginseng fields (Example 1). Each group consisted of 10 animals. All administration solutions were orally administered to rats in a volume of 20 mLZkg, and the control group was orally administered the same amount of distilled water. Except for the normal group, the test substance was orally administered to the three groups once a day for 7 days, and 400 mg Zkg of galactosamine was intravenously administered on the last day for liver injury. Was caused.
  • a gelatin solution consisting of 43% by weight of gelatin, 17% by weight of glycerin and 40% by weight of water is dissolved and degassed at 80 ° C, and then left standing for about 10 hours to be filled with a rotary soft capsule filling machine (Oval 5 type). ), 180 mg of perilla oil in which 150 mg of the powder of Example 1 was dissolved, 2 mg of soybean lecithin, and 18 mg of phytic acid were filled. After filling the capsules, the capsules were dried at a temperature of 27 ° C and a humidity of 50% or less to a film moisture of 8%. Soft capsules were produced.
  • Example 1 In order to examine the hepatoprotective effect of the composition obtained in Example 1 and the raw rice ginseng, Reference Example 1 composition and Reference Example 2 composition, a rat galactosamine-induced liver injury model and tetrasalt An experiment was performed using a dani carbon-induced liver injury model. It is known that the extra-gala samin-induced liver injury model is a viral hepatitis model, and the Shishi-dani carbon-induced liver injury model is an toxic hepatitis model, which has high correlation with clinical results.
  • the experimental group was a normal group, a control group, a raw ginseng 3.OgZ kg administration group, Reference Example 1 composition 3.OgZkg administration group, Reference Example 2 composition 3.3gZkg administration group and Example 1 composition 3.
  • test substance was orally administered once daily for 4 days to 5 groups except the normal group, and 400 mg Zkg of galactosamine was intravenously administered on the last day to induce liver injury.
  • 400 mg Zkg of galactosamine was intravenously administered on the last day to induce liver injury.
  • Shisho-Dani-Carbon-induced liver injury model the test substance was orally administered once daily for 5 days to five groups except the normal group, and on the last day, 0.75 mL Was administered intraperitoneally to induce liver damage.
  • Twenty-four hours after the administration of extra-gala samin (or tetrashidani carbon) blood was collected from the abdominal aorta and the GPT activity in the plasma was measured using a transaminase CII test.
  • FIG. 1 is a graph comparing the effects of hepatoprotection on GPT activity in an acute liver injury model induced by galactosamine.
  • FIG. 2 is a graph comparing the effects of hepatoprotective action on GOT activity in an acute liver injury model induced by galactosamine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

Selon l'invention, l'effet du ginseng destiné à un usage médicinal (amélioration de la fonction hépatique, effet hémostatique, effet antistress, effet antitumoral, effet antiviellissement, effet antioxydatif, etc.) peut être amélioré par une méthode de traitement qui consiste à placer une plante de ginseng ou son extrait au contact d'un micro-organisme ou d'une enzyme, puis à mettre la plante de ginseng ou son extrait en réaction avec un acide ou un alcali. Le produit ainsi traité peut être utilisé comme aliment, médicament, produit cosmétique, etc.
PCT/JP2004/014265 2003-09-30 2004-09-29 Methode de traitement du ginseng pour un usage medicinal, et composition WO2005030235A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2005514260A JP4767686B2 (ja) 2003-09-30 2004-09-29 肝保護用医薬
HK07103793.6A HK1096042A1 (en) 2003-09-30 2007-04-12 Method of processing ginseng for medicinal use and composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003339752 2003-09-30
JP2003-339752 2003-09-30

Publications (1)

Publication Number Publication Date
WO2005030235A1 true WO2005030235A1 (fr) 2005-04-07

Family

ID=34386187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/014265 WO2005030235A1 (fr) 2003-09-30 2004-09-29 Methode de traitement du ginseng pour un usage medicinal, et composition

Country Status (4)

Country Link
JP (1) JP4767686B2 (fr)
CN (1) CN100586444C (fr)
HK (1) HK1096042A1 (fr)
WO (1) WO2005030235A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092275A1 (fr) * 2007-02-02 2008-08-07 Pos Pilot Plant Corp. Extraction de produits phytochimiques par hydrolyse enzymatique
WO2009063987A1 (fr) * 2007-11-15 2009-05-22 Wakunaga Pharmaceutical Co., Ltd. Nouvelle utilisation de ginseng traité
WO2009104902A3 (fr) * 2008-02-19 2009-12-03 Unigen, Inc. Composition permettant d'améliorer la performance d'exercice, la récupération de fatigue et l'activité antioxydante comprenant un extrait de feuilles de plante de l' espèce panax ou d'extrait de feuilles de plante de l'espèce panax transformé ou un mélange des deux
JP2010011847A (ja) * 2008-06-04 2010-01-21 Morikawa Kenkodo Kk 血圧降下作用を有するローヤルゼリーの製造方法
KR20120097516A (ko) 2009-12-21 2012-09-04 라이온 가부시키가이샤 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품
JP2012527233A (ja) * 2009-05-19 2012-11-08 イル・ファ・カンパニー・リミテッド 発酵高麗人参濃縮液または粉末の製造方法
JP2013529899A (ja) * 2010-05-14 2013-07-25 株式会社ジーシーエイチアンドピー ジンセノサイド成分を増加させた新規な加工人参または加工人参抽出物の製造方法
US8604010B2 (en) 2008-09-09 2013-12-10 Lion Corporation Method for producing high sapogenin content composition
KR101458274B1 (ko) * 2012-10-08 2014-11-04 주식회사 한국인삼공사 인삼 발효추출물을 함유하는 화장료 조성물
WO2015029134A1 (fr) * 2013-08-27 2015-03-05 金氏高麗人参株式会社 Composition de ginsénoside
KR20150034444A (ko) * 2013-09-26 2015-04-03 샘표식품 주식회사 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법
KR20160014096A (ko) * 2016-01-27 2016-02-05 샘표식품 주식회사 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법
US10709749B2 (en) 2013-08-30 2020-07-14 Green Cross Wellbeing Corporation Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100997054B1 (ko) * 2010-06-11 2010-11-30 홍진석 산양삼의 발효방법 및 이로부터 제조된 발효 산양삼
CN102091022A (zh) * 2010-09-08 2011-06-15 成进学 纳米硒ve防皱抗衰嫩肤霜
CN103284940B (zh) * 2013-06-28 2014-08-06 上海生态美日化有限公司 酵母菌发酵中药组合物及其制备方法和应用
CN103446209B (zh) * 2013-08-11 2016-04-13 吉林农业大学 一种基于α-淀粉酶制备人参浆的方法
CN103463152A (zh) * 2013-08-11 2013-12-25 吉林农业大学 一种利用葡萄糖淀粉酶制备人参浆的方法
CN103446208B (zh) * 2013-08-11 2018-06-19 吉林农业大学 一种利用纤维素酶制备人参浆的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05161481A (ja) * 1991-12-11 1993-06-29 Nitto Denko Corp 改質薬用人参エキスならびにその製造方法および用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0683656B2 (ja) * 1985-11-26 1994-10-26 日東電工株式会社 薬用人参クリ−ムの製造方法
JP3238192B2 (ja) * 1992-04-01 2001-12-10 江崎グリコ株式会社 動植物中の有用成分を濃縮し精製する方法
JPH11169135A (ja) * 1997-12-10 1999-06-29 Nagaoka Jitsugyo Kk 薬用人参加工酸味液及びその製造方法
JP4549625B2 (ja) * 2002-01-05 2010-09-22 株式會社アモーレパシフィック 人参サポニン代謝産物を有効成分とする微細乳化粒子及びその製造方法、並びにこれを含有する皮膚老化防止用の化粧料組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05161481A (ja) * 1991-12-11 1993-06-29 Nitto Denko Corp 改質薬用人参エキスならびにその製造方法および用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KARIKURA M. ET AL.: "Studies on absorption, distribution, excretion and metabolism of Ginseng saponins. VII. Comparison of the decempotion modes of ginsenoside-Rb1 and Rb2 in the digestive tract of rats", CHEM. PHARM. BULL., vol. 39, no. 9, 1991, pages 2357 - 2361, XP009035585 *
KO S.R. ET AL.: "Enzymatic preparation of Ginsenoside Rg2, Rh1, and F1", CHEM. PHARM. BULL., vol. 51, no. 4, 1 April 2003 (2003-04-01), pages 404 - 408, XP002986275 *
NANBA T. ET AL.: "Denshichininjin no miryoku", BIOTHERAPY, vol. 14, no. 10, 2000, pages 999 - 1008, XP002986280 *
PRASAIN J.K. ET AL.: "13-3. Studies on hepatoprotective effect of Panax notoginseng: ginsenosides-Re and -Rg1 as its active constituents", THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI KOEN YOSHISHU, vol. 116, no. 2, 1996, pages 236, XP002986277 *
USHIJIMA M. ET AL.: "Denshichininjin no kanhogo.koensho sayo", NIHON MATSUBYO SYSTEM GAKKAI, vol. 9, 2002, pages 49, XP002986276 *
YOSHIKAWA M. ET AL.: "Bioactive saponins and glycosides. VIII. Notoginseng (1): New dammarane-type triterpene oligoglycosides, notoginsenoside-A, -B, -C, and -D, from the dried root of Panax notoginseng (Burk.)", CHEM. PHARM. BULL., vol. 45, no. 6, 1997, pages 1039 - 1045, XP002986278 *
YOSHIKAWA M. ET AL.: "Structures of new dammarane-type triterpenes saponins from the flower buds of Panax notoginseng and hematoprotective effects of principal ginseng saponins", J. NAT. PROD., vol. 66, no. 7, July 2003 (2003-07-01), pages 922 - 927, XP002986279 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092842B2 (en) 2007-02-02 2012-01-10 Pos Pilot Plant Corporation Extraction of phytochemicals by enzymatic hydrolysis
WO2008092275A1 (fr) * 2007-02-02 2008-08-07 Pos Pilot Plant Corp. Extraction de produits phytochimiques par hydrolyse enzymatique
WO2009063987A1 (fr) * 2007-11-15 2009-05-22 Wakunaga Pharmaceutical Co., Ltd. Nouvelle utilisation de ginseng traité
JPWO2009063987A1 (ja) * 2007-11-15 2011-03-31 湧永製薬株式会社 加工薬用人参の新規用途
WO2009104902A3 (fr) * 2008-02-19 2009-12-03 Unigen, Inc. Composition permettant d'améliorer la performance d'exercice, la récupération de fatigue et l'activité antioxydante comprenant un extrait de feuilles de plante de l' espèce panax ou d'extrait de feuilles de plante de l'espèce panax transformé ou un mélange des deux
JP2010011847A (ja) * 2008-06-04 2010-01-21 Morikawa Kenkodo Kk 血圧降下作用を有するローヤルゼリーの製造方法
US8604010B2 (en) 2008-09-09 2013-12-10 Lion Corporation Method for producing high sapogenin content composition
JP2012527233A (ja) * 2009-05-19 2012-11-08 イル・ファ・カンパニー・リミテッド 発酵高麗人参濃縮液または粉末の製造方法
EP2702996A1 (fr) 2009-12-21 2014-03-05 Lion Corporation Composition d'amélioration de l'anémie
US8927033B2 (en) 2009-12-21 2015-01-06 Lion Corporation Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and food or beverage
KR20120097516A (ko) 2009-12-21 2012-09-04 라이온 가부시키가이샤 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품
KR20160101724A (ko) 2009-12-21 2016-08-25 라이온 가부시키가이샤 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품
US9512453B2 (en) 2010-05-14 2016-12-06 Green Cross Wellbeing Corporation Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased
JP2013529899A (ja) * 2010-05-14 2013-07-25 株式会社ジーシーエイチアンドピー ジンセノサイド成分を増加させた新規な加工人参または加工人参抽出物の製造方法
KR101458274B1 (ko) * 2012-10-08 2014-11-04 주식회사 한국인삼공사 인삼 발효추출물을 함유하는 화장료 조성물
WO2015029134A1 (fr) * 2013-08-27 2015-03-05 金氏高麗人参株式会社 Composition de ginsénoside
US10709749B2 (en) 2013-08-30 2020-07-14 Green Cross Wellbeing Corporation Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent
US11464821B2 (en) 2013-08-30 2022-10-11 Green Cross Wellbeing Corporation Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2
KR20150034444A (ko) * 2013-09-26 2015-04-03 샘표식품 주식회사 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법
KR101591251B1 (ko) * 2013-09-26 2016-02-03 샘표식품 주식회사 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법
KR20160014096A (ko) * 2016-01-27 2016-02-05 샘표식품 주식회사 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법
KR102073691B1 (ko) 2016-01-27 2020-02-05 샘표식품 주식회사 강화된 진세노사이드 및 어글리콘을 포함하는 인삼 또는 산삼배양근, 및 그의 가공방법

Also Published As

Publication number Publication date
HK1096042A1 (en) 2007-05-25
JP4767686B2 (ja) 2011-09-07
JPWO2005030235A1 (ja) 2007-11-15
CN100586444C (zh) 2010-02-03
CN1859921A (zh) 2006-11-08

Similar Documents

Publication Publication Date Title
JP4767686B2 (ja) 肝保護用医薬
CN104824548B (zh) 枸杞复合保健酵素及其制备方法
KR100988072B1 (ko) 황칠나무 발효물 및 그것을 포함하는 약학 조성물
JP4520386B2 (ja) ニンニクから得られる発酵物
EP1813309A1 (fr) Composition d'elimination de proteine anormale
KR20140052576A (ko) 식물 발효 추출물을 포함하는 프리바이오틱 화장료 조성물
KR101768806B1 (ko) 두릅나무과 식물의 발효물을 포함하는 항염증 또는 항암용 조성물
JP2018193341A (ja) 植物発酵物
KR101840508B1 (ko) 피부 미용 촉진제 및 그의 이용
US20080261896A1 (en) Testosterone generating and metabolizing enhancer
JP5072369B2 (ja) 幹細胞増殖因子発現上昇抑制剤及び塩基性線維芽細胞増殖因子発現上昇抑制剤
JP7418853B2 (ja) 皮膚外用剤
JP2005000161A (ja) トウガラシ又はカプシノイド含有植物の発酵組成物
KR20160013731A (ko) 진세노사이드 Ｒｈ２와 Ｒｇ３의 함량이 증진된 인삼 발효물의 제조 방법
JP2019038760A (ja) 皮膚外用剤
JP2006061091A (ja) シソの葉から得られる発酵物
JP7489688B2 (ja) 皮膚外用剤
JP2017105745A (ja) 皮膚外用剤
KR20170106187A (ko) 항산화용 조성물
JP2006075083A (ja) ゴーヤから得られる発酵物
KR102167812B1 (ko) 장건강 및 장개선 효능을 가지는 수수 및 팥 발효물 및 이의 제조방법
KR101960571B1 (ko) 살구 추출물의 제조방법, 이로부터 제조된 살구 추출물 및 이를 유효 성분으로 포함하는 기능성 피부미용 또는 화장료 조성물
KR102239415B1 (ko) 발효 삼칠근의 추출물을 포함하는 피부미용 개선용 조성물
JP2021172593A (ja) 皮膚外用剤
JP6158147B2 (ja) 美白剤及びこれを含有する内用又は外用組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480028083.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005514260

Country of ref document: JP

122 Ep: pct application non-entry in european phase